# Capecitabine in Low Risk Triple Negative Breast Cancer

> **NCT06787339** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 198 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06787339
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-15
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 198 (ESTIMATED)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06787339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06787339, "Capecitabine in Low Risk Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06787339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*